Evidence map›Paper›PMID 41787258›Full record

ArticleBMC microbiology2026

Combination of 7-hydroxyflavone and colistin: antibacterial activity and mechanism against multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.

Mengjie Wei, Ziyue Zeng, Fan Ye, Xiaowei Lv, Zhuocheng Yao, Deyi Zhao, Tieli Zhou, Lijiang Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mengjie WeiDepartment of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
Ziyue ZengDepartment of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
Fan YeDepartment of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
Xiaowei LvDepartment of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
Zhuocheng YaoDepartment of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
Deyi ZhaoSchool of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
Tieli ZhouDepartment of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China. wyztli@163.com.
Lijiang ChenDepartment of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China. wyychenlijiang@163.com.

Funding

the Consortium for Infection and Innovation (CII) Research Grant of the First Affiliated Hospital of Wenzhou Medical University Project No.: 2025WMU-X001
6 · The paper itself

Abstract

backgroundWith the continuous escalation of resistance of Pseudomonas aeruginosa and Acinetobacter baumannii to first line antibiotics such as colistin (COL), the development of novel therapeutic strategies is urgently required.

resultsThis study demonstrates for the first time that 7-hydroxyflavone (7-HF) can restore COL’s bactericidal activity against clinically resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and the synergistic effect of 7-HF combined with COL was confirmed by both checkerboard and time-kill curves. The anti-biofilm effect of COL combined with 7-HF was evaluated by biofilm inhibition assay. Safety assessments, including cytotoxicity and erythrocyte hemolysis tests, indicated that both monotherapy and combination regimens were well-tolerated. In addition, the combined use of COL and 7-HF reduced the bacterial load in a mouse thigh infection model.

conclusionsOur findings may provide a clinically safe and effective strategy for combating multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii infections.

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsColistinDrug Resistance, Multiple, BacterialFlavonesPseudomonas aeruginosaAcinetobacter InfectionsAnimalsBiofilmsDrug SynergismHumansMiceMicrobial Sensitivity TestsPseudomonas InfectionsAnti-Bacterial AgentsColistinFlavones7-hydroxyflavoneAntimicrobial adjuvantAntimicrobial resistanceColistinSynergistic effect

Identifiers

PMID41787258
PMCPMC13077889

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.